Bridgeway Capital Management LLC Purchases 11,149 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Bridgeway Capital Management LLC lifted its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 3.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 358,785 shares of the company's stock after purchasing an additional 11,149 shares during the quarter. Bridgeway Capital Management LLC owned about 0.78% of Pacira BioSciences worth $6,760,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in PCRX. Sterling Capital Management LLC increased its stake in Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after buying an additional 1,208 shares during the period. Ancora Advisors LLC purchased a new stake in shares of Pacira BioSciences in the 4th quarter valued at approximately $26,000. Caitlin John LLC raised its position in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after buying an additional 1,776 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after purchasing an additional 2,749 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after buying an additional 513 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Trading Up 0.5%

NASDAQ PCRX traded up $0.12 during trading on Monday, hitting $25.24. The stock had a trading volume of 403,339 shares, compared to its average volume of 961,522. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -12.43 and a beta of 0.56. The stock has a 50 day simple moving average of $24.73 and a 200 day simple moving average of $22.17. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $31.67.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PCRX. HC Wainwright boosted their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Needham & Company LLC reduced their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and increased their price objective for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. Barclays raised their price target on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $26.44.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.